Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).

Gastrointestinal Cancer

Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, and capecitabine with or without IMAB362, as first-line treatment of gastric and gastroesophageal junction adenocarcinoma (Abstract LBA4001).

Solid Tumors

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).

Global Cancer Care

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).

Kidney Cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and potential predictors of benefit (Abstract 4507).

Jun

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial

Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

Early-Stage Breast Cancer: Losing Weight, Gaining Quality of Life

New Research Links Low Alcohol Consumption to Elevated Health Risks

Digital Tool May Improve Patient Engagement in Oncology Clinical Trials

GLP-1 RAs May Reduce Risk of Obesity-Related Cancers

Teclistamab in Previously Treated Multiple Myeloma